SpaceX (NASDAQ: SPCX) has captured the imagination of retail and institutional investors alike, with its revolutionary reusable rocket technology and ambitious artificial intelligence ventures driving the stock to a valuation approaching $2 trillion. However, the space exploration company generated just $7.8 billion in revenue during its latest quarter while remaining unprofitable—a combination that has some market participants questioning whether better opportunities exist elsewhere. Two names surfacing as potential alternatives are Intuitive Surgical (NASDAQ: ISRG) and Veeva Systems (NYSE: VEEV), both of which offer exposure to high-growth markets with more established business models.
Market Context
The broader equity market has witnessed remarkable concentration in mega-cap growth names, with SpaceX joining the ranks of companies commanding premium valuations based on future potential rather than current profitability. Intuitive Surgical, the dominant player in robotic-assisted surgery, has underperformed the broader market in 2026 as investors weighed margin pressures from its newest da Vinci 5 system rollout against competitive threats from healthcare giants Medtronic and Johnson & Johnson. Meanwhile, Veeva Systems has been slowly recovering from its own turbulence, demonstrating resilience amid widespread concerns about AI disruption affecting traditional software business models.
Analysis
Intuitive Surgical's underperformance this year stems primarily from near-term headwinds rather than structural problems with its core business. The company's da Vinci 5 system represents a meaningful technological advancement, featuring Force Feedback Technology that allows surgeons to gauge instrument pressure on patient tissues during procedures—an innovation aimed at reducing injuries and improving outcomes. While the system's rollout has compressed margins in the short term, the installed base expansion suggests long-term revenue visibility. The company ended the second quarter with 11,710 da Vinci systems deployed globally, representing a 12% year-over-year increase that demonstrates continued demand for robotic-assisted surgery capabilities.
Veeva Systems presents a different value proposition as a cloud-based software provider serving the life sciences industry. Rather than facing existential threats from AI competitors, Veeva has demonstrated that its specialized platforms for pharmaceutical companies can coexist with broader AI adoption across healthcare. The stock's gradual recovery signals investor confidence in the company's ability to maintain its market position while adapting its offerings to incorporate artificial intelligence capabilities.
The SpaceX valuation premium reflects substantial long-term opportunity across space travel, satellite internet, and potential AI applications, but any operational setback could trigger significant downside given current expectations embedded in the stock price. For investors seeking exposure to transformative technologies without the binary risk profile of an unprofitable company at a $2 trillion valuation, Intuitive Surgical and Veeva Systems offer established market positions with proven business models.
Key Numbers
- SpaceX market capitalization: approximately $2 trillion
- SpaceX quarterly revenue: $7.8 billion (unprofitable)
- Intuitive Surgical Q2 installed base: 11,710 da Vinci systems (+12% year-over-year)
- Medtronic and Johnson & Johnson cited as emerging competitors in robotic-assisted surgery
- Veeva Systems showing gradual recovery amid AI sector concerns
What to Watch
For ISRG, the upcoming earnings season will be critical for gauging whether margin pressures from the da Vinci 5 rollout have peaked. Investors should monitor procedure volume growth rates and international expansion momentum as indicators of sustained demand. Key support levels to watch include the stock's 200-day moving average, while resistance sits at prior highs established before the underperformance period began.
For VEEV, upcoming product announcements regarding AI integration into its life sciences platform could serve as catalysts for renewed institutional interest. The company's ability to demonstrate customer retention amid competitive pressures in the healthcare software space will be a focal point. Traders should track volume patterns around earnings dates and any news flow related to pharmaceutical industry spending on digital infrastructure.